Welcome to our dedicated page for Angiodynamics SEC filings (Ticker: ANGO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
AngioDynamics, Inc. filings document regulatory disclosures for a Nasdaq-listed medical technology company focused on vascular disease, thrombectomy, oncology and surgical device markets. Recent Form 8-K reports furnish quarterly and annual financial results, Regulation FD investor presentation materials, and forward-looking statement language tied to product strategy, competitive position, cash flows and operating plans.
The filing record also covers governance and material-event disclosures, including annual meeting voting results, director elections, auditor ratification, advisory executive-compensation votes, executive transition and retirement arrangements, and patent-enforcement litigation involving the company’s thrombectomy intellectual property and self-expanding funnel technology. Proxy materials provide compensation tables, board matters and shareholder-vote mechanics.
AngioDynamics, Inc. received an updated large-shareholder disclosure showing that investment entities affiliated with Millennium reported modest, passive stakes in its common stock. Integrated Core Strategies (US) LLC reported beneficial ownership of 551,565 shares, representing 1.3% of AngioDynamics’ common stock. Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander each reported beneficial ownership of 842,548 shares, or 2.0% of the outstanding common stock, as of the event date of 12/31/2025. The filers certify that the securities were not acquired and are not held for the purpose of changing or influencing control of AngioDynamics.
AngioDynamics, Inc. reported stockholder voting results. Shareholders elected two directors: James C. Clemmer received 29,634,152 votes for and 800,454 withheld, with 5,462,943 broker non-votes; Michael E. Tarnoff, MD received 29,245,896 votes for and 1,188,710 withheld, with 5,462,943 broker non-votes.
Stockholders also approved two additional items. One item received 35,727,186 votes for, 156,899 against, and 13,464 abstentions; there were no broker non-votes for this item. Another item received 28,357,782 votes for, 2,057,982 against, 18,842 abstentions, and 5,462,943 broker non-votes.
AngioDynamics (ANGO) reported an insider open‑market purchase. On 10/21/2025, an officer serving as SVP, Chief Legal Officer bought 10,000 shares of common stock, coded “P” for purchase. The weighted average price was $11.81, with trades executed between $11.71 and $11.90. After this transaction, the reporting person beneficially owned 93,597 shares, held directly. The filing notes the weighted‑average pricing and that detailed trade‑by‑trade data within the price range is available upon request.
AngioDynamics, Inc. filed a Form S-8 to register 4,700,000 shares of common stock for issuance under its 2020 Equity Incentive Plan, as approved by shareholders on November 14, 2023 and November 12, 2024.
The filing also includes a Reoffer Prospectus covering the potential resale, from time to time, of up to 2,529,068 shares by certain employees and officers who acquired awards under the plan. The company will receive no proceeds from sales by the selling stockholders, while bearing registration expenses. AngioDynamics’ common stock trades on Nasdaq as “ANGO,” and the last reported sale price was $11.82 per share on October 20, 2025.
Shares outstanding were 41,076,119 as of September 18, 2025; this is a baseline figure, not the amount being registered or resold.
AngioDynamics (ANGO) reported insider activity by its EVP and CFO. A Form 4 shows a purchase of 890 shares of common stock on 10/13/2025 at a price of $11.16 per share, coded “P” for a purchase.
Following the transaction, the reporting person beneficially owns 256,629 shares, held directly. The filing indicates the role as EVP and CFO and confirms the report was filed by one reporting person.
James C. Clemmer, President, CEO and a director of AngioDynamics, Inc. (ANGO), reported an insider purchase of common stock on 10/09/2025. The filing shows a purchase of 10,000 shares at a weighted average price of $11.15, with trade prices in the range $11.10 to $11.17. After the transaction the reporting person beneficially owns 882,529 shares.
The filing is a standard Section 16 Form 4 disclosing a direct purchase by the reporting person. The filer notes the purchase occurred in multiple transactions and offers to provide a breakdown of quantities by price on request. No derivative transactions or dispositions are reported.
AngioDynamics Inc. reported first-quarter fiscal 2026 net sales of $75.7 million, up 12.2% from the prior-year quarter, driven by Med Tech growth of 26.1% (Auryon, NanoKnife, thrombus management) and modest Med Device growth of 2.3%. Gross margin rose 90 basis points to 55.3%. The company recorded a net loss of $10.9 million (loss per share $0.26), an improvement from a $12.8 million loss a year earlier.
The company continues restructuring actions with $2.3 million in charges this quarter and $25.6 million total recorded to date. A settlement with BD (Becton, Dickinson) includes a one-time lump-sum structure and ongoing minimum annual payments; $2.5 million was paid this quarter and a contingent $3.0 million may be due depending on the Federal Circuit appeal (oral argument set for October 8, 2025). Management maintains a valuation allowance on deferred tax assets and noted continued macroeconomic and supply-chain risks. The company has a $25.0 million revolving credit facility with $0 drawn as of August 31, 2025.
AngioDynamics, Inc. filed a current report to furnish its financial results for the fiscal first quarter ended August 31, 2025. The company issued a press release with these results, attached as Exhibit 99.1, and also provided investor presentation slides discussing the quarter as Exhibit 99.2.
The company emphasizes that these materials are being furnished rather than filed, which limits certain securities law liabilities and controls how they are incorporated into other SEC documents. It also includes extensive forward-looking statement language, highlighting risks such as the impact of COVID-19, regulatory actions, competition, product development, litigation, economic conditions, and other factors referenced in its latest annual report.
AngioDynamics (ANGO) requests shareholder votes at its Annual Meeting on November 10, 2025, including election of two Class I directors, ratification of Deloitte & Touche LLP as auditor and an advisory "Say-on-Pay" vote. Shareholders of record as of September 18, 2025 (41,076,119 shares) may vote in person or virtually at www.virtualshareholdermeeting.com/ANGO2025. The Board describes its enterprise risk oversight process, delegating specific risks to committees and noting the Audit Committee met eight times and includes an audit committee financial expert. CEO compensation was largely performance-based (67% target) and the CEO-to-median employee pay ratio is approximately 44:1. The proxy discloses director retainer and equity grant practices, Compensation Committee use of Meridian for benchmarking, and change-in-control and severance arrangements for executives.
Armistice Capital and Steven Boyd report a passive 3.76% stake in AngioDynamics (ANGO). The filing states Armistice Capital, as investment manager to Armistice Capital Master Fund Ltd., and Steven Boyd, as managing member, share voting and dispositive power over 1,527,815 shares. The stake is based on 40,633,885 shares outstanding as of May 31, 2025, per the issuer's 10-K. The Reporting Persons state the holdings were acquired in the ordinary course of business and not to influence control of the company. The Master Fund is the direct holder while Armistice exercises voting and investment authority under an investment management agreement.